Matinas BioPharma (NYSEAMERICAN:MTNB) Issues Earnings Results

Matinas BioPharma (NYSEAMERICAN:MTNB) posted its quarterly earnings data on Wednesday. The company reported ($0.03) earnings per share for the quarter, Yahoo Finance reports.

Matinas BioPharma Price Performance

Shares of NYSEAMERICAN MTNB opened at $0.28 on Thursday. Matinas BioPharma has a 52 week low of $0.11 and a 52 week high of $0.89.

Institutional Investors Weigh In On Matinas BioPharma

Hedge funds have recently modified their holdings of the business. BlackRock Inc. grew its holdings in shares of Matinas BioPharma by 0.7% in the first quarter. BlackRock Inc. now owns 4,325,053 shares of the company’s stock valued at $3,479,000 after purchasing an additional 29,643 shares during the period. Atria Wealth Solutions Inc. purchased a new stake in shares of Matinas BioPharma in the first quarter valued at about $32,000. HRT Financial LP boosted its stake in Matinas BioPharma by 320.5% during the fourth quarter. HRT Financial LP now owns 54,567 shares of the company’s stock worth $27,000 after buying an additional 41,590 shares during the period. Renaissance Technologies LLC increased its position in shares of Matinas BioPharma by 42.0% during the first quarter. Renaissance Technologies LLC now owns 171,929 shares of the company’s stock valued at $81,000 after acquiring an additional 50,833 shares during the last quarter. Finally, State Street Corp increased its position in shares of Matinas BioPharma by 8.0% during the first quarter. State Street Corp now owns 712,471 shares of the company’s stock valued at $573,000 after acquiring an additional 52,897 shares during the last quarter. 11.77% of the stock is currently owned by institutional investors and hedge funds.

About Matinas BioPharma

Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.